Posters & Presentations

Optimizing drug development in populations with compensated MASH cirrhosis by integration of the Disease Severity Index from the HepQuant DuO test in trial design

J.C. Imperial, M.P. McRae, G.T. Everson | EASL Congress May 2026

Presentation Image